A Phase 4 interventional study of Sofosbuvir/Velpatasvir Treatment for 14 days in Hepatitis C, sponsored by Massachusetts General Hospital. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-21.
Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Prevention
This is an unblinded, observational trial of sofosbuvir-velpatasvir in adult health care workers who are exposed to hepatitis C virus from needlestick injury with hollow-bore needles.
The goal of this study is to assess the safety and tolerability of the use of sofosbuvir-velpatasvir in the setting of post-exposure prophylaxis among Health Care Workers exposed to HCV from needlestick injury with hollow-bore needles
Exclusion Criteria:
14 days of treatment with Sofosbuvir/Velpatasvir tablet
Drug: Sofosbuvir/Velpatasvir Treatment for 14 days
14 day therapy with Sofosbuvir/Velpatasvir
Also known as: Epclusa
Undetectable HCV RNA
Negative HCV viral RNA at 12 weeks after the last dose of treatment.
Time frame: 12 weeks post treatment
Plan to share: No — no plan currently to share IPD with other researchers
No publications or documents are linked to this record.
This study is withdrawn, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital